

CRO Communiqué
Keeping you informed about CRO progress
December 2013

Top Enrolling Physicians for November 2013

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Bonebrake	1	1	0	1
Dr. Carlson (Mercy Spfld)	3	1	2.5	3.5
Dr. Ellis (Cox)	1	0	1	1
Dr. Finnie (Mercy St. Louis)	1	0	1	1
Dr. Mary Graham (Phelps)	1	1	0.3	1.3
Dr. Hanson (Mercy St. Louis)	1	2	0	2
Dr. Holden (Mercy Spfld)	1	1	0	1
Dr. Luedke (Mercy St. Louis)	1	0	1	1
Dr. Miller (Freeman)	1	2.5	0	2.5
Dr. Oza (Good Samaritan)	3	1	1	2
Dr. Raju (Mercy Spfld)	1	1	0	1
Total	15	10.5	6.8	17.3

November was a very slow month for CRO enrollments. With half of our grant year behind us we have earned 50.8 treatment credits and need to be at 75.8 to be on track to reach our grant year target of 130 treatment credits. We have earned 59.6 cancer control credits and need to have earned 70 control credits to be on track to meet this year cancer control target of 140. Please be diligent with placing patients onto trials. Attached is “CRO’s Patient Registration Summary’ updated through November.

NCORP Grant

The NCORP grant request for application was released on November 8th. It is due on January 8, 2014. We are working hard to prepare the grant. Health Care Delivery is a new component of the grant. NCI will be holding a webinar on Monday, December 2nd to discuss the health care delivery component.

CRO Fall Steering Committee Meeting

CRO’s fall Steering Committee meeting was held on Thursday, November 21st. Joseph M Anderson, MD FCAP from Redwood City, California spoke on Genomics in Cancer treatment the past, present and the future. Thirty-four attended this event. Special thanks to Genomic Health and Amy Kidwell.

Profile Study

SWOG S1211 “A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)” is our profile study this month. This trial is studying the side effects, best dose of elotuzumab and to see how well it works when given with lenalidomide, bortezomib, and dexamethasone in treating patients with multiple myeloma. Lenalidomide and bortezomib may stop the growth of multiple myeloma by blocking blood flow to the tumor. Also, bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as elotuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as lenalidomide and dexamethasone also work in different ways to kill tumor cells or stop them from growing. Giving elotuzumab together with chemotherapy may be a better way to block cancer growth. This study is going to our local IRBs in December for approval.



*A Very Merry Christmas and Happy New Year to you!
 Thank you for your commitment to CRO clinical research.
 From the Staff at Cancer Research for the Ozarks*

**New Studies Approved in November, 2013 Through Cox & Mercy
Springfield's IRB's**

SWOG S1304 "A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease"

New Studies Approved in November, 2013 Through Cox IRB's

CALGB 50801 "A Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)" approved last month at Mercy Springfield

New Studies Opened in November with the CIRB

None

**Studies sent to Cox & Mercy IRB's for Permanent Closure in November
2013**

GOG 0267 Quality of Life and Care Needs in Patients with Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube and Peritoneal Cancer